UA44667A - Спосіб отримання протилептоспірозного імуноглобуліну - Google Patents
Спосіб отримання протилептоспірозного імуноглобуліну Download PDFInfo
- Publication number
- UA44667A UA44667A UA98031331A UA98031331A UA44667A UA 44667 A UA44667 A UA 44667A UA 98031331 A UA98031331 A UA 98031331A UA 98031331 A UA98031331 A UA 98031331A UA 44667 A UA44667 A UA 44667A
- Authority
- UA
- Ukraine
- Prior art keywords
- leptospirosis
- immunoglobulin
- obtaining
- blood
- antyleptospirose
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 22
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 10
- 206010024238 Leptospirosis Diseases 0.000 claims abstract description 32
- 108010074605 gamma-Globulins Proteins 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000002955 isolation Methods 0.000 abstract description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003199 anti-leptospiral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Изобретение относится к иммунологии и микробиологии и может быть использовано для специфической иммунотерапии больных лептоспирозом, а также для промышленного производства препарата противолептоспирозного иммуноглобулина. Способ получения противолептоспирозного иммуноглобулина гамма-глобулиновой фракции крови предусматривает получение иммуноглобулина из гамма-глобулиновой фракции крови людей-доноров.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA98031331A UA44667A (uk) | 1998-03-17 | 1998-03-17 | Спосіб отримання протилептоспірозного імуноглобуліну |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA98031331A UA44667A (uk) | 1998-03-17 | 1998-03-17 | Спосіб отримання протилептоспірозного імуноглобуліну |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA44667A true UA44667A (uk) | 2002-02-15 |
Family
ID=74198113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA98031331A UA44667A (uk) | 1998-03-17 | 1998-03-17 | Спосіб отримання протилептоспірозного імуноглобуліну |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA44667A (ru) |
-
1998
- 1998-03-17 UA UA98031331A patent/UA44667A/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sutherland | Antivenom to the Venom of the Male Sydney Funnel‐Web Spider Atrax Robustus: Preliminary Report | |
| Brooks et al. | Encephalitis caused by Coxiella burnetii | |
| Wicher et al. | Cell response in rabbits infected with T. pallidum as measured by the leucocyte migration inhibition test. | |
| Rubin et al. | Immunoglobulin response to rabies vaccine in man | |
| UA44667A (uk) | Спосіб отримання протилептоспірозного імуноглобуліну | |
| US7217541B2 (en) | Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections | |
| HowARD et al. | The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study | |
| AT410636B (de) | Verfahren zur herstellung eines impfstoffes | |
| Hodgson et al. | Prophylactic use of human endotoxin-core hyperimmune gammaglobulin to prevent endotoxaemia in colostrum-deprived, gnotobiotic lambs challenged orally with Escherichia coli | |
| CN111620947B (zh) | 一种二价抗海蛇毒血清的制备方法 | |
| South et al. | The IgA antibody system | |
| RU2105310C1 (ru) | Способ лечения синдрома приобретенного иммунного дефицита (спид) | |
| RU2062109C1 (ru) | Способ получения иммунного препарата | |
| WO1997037636A1 (en) | Therapeutic and preventive method against harmful microbes | |
| CN114073766A (zh) | 一种幽门螺杆菌表位肽及其应用 | |
| Rindi et al. | Antibody response to Staphylococcal slime and lipoteichoic acid | |
| TWI511743B (zh) | 抗血清、中和抗體、及含其之醫藥組合物 | |
| OA10028A (en) | Process for the remission of symptoms associated with aids | |
| RU2257216C2 (ru) | Иммуномодулирующее средство риботаб | |
| RU2180238C1 (ru) | Биологический препарат для профилактики и лечения желудочно-кишечных и респираторных болезней телят | |
| RU2120300C1 (ru) | Способ получения эритроцитарного антигенного диагностикума | |
| Sergo et al. | DEVELOPMENT OF IMMUNOGLOBULIN FOR TREATMENT OF COMPLICATED STAPHYLOCOCCAL INFECTION. | |
| Yadav et al. | PRODUCTION OF POLYCLONAL ANTIBODIES AGAINST INDIAN CATTLE TICK RHIPICEPHALUS MICROPLUS SALIVA TOXINS AND ITS EFFICACY IN REVERSAL OF TOXIC EFFECTS IN ALBINO MICE | |
| Abrutyn et al. | Cholera in a vaccinated American: immunological response to vaccination and disease | |
| Takayama et al. | Successful Treatment of Necrotizing Fasciitis Following Cat Bites in an Immunocompromised Patient by Ampicillin-Sulbactam and Intravenous Immunoglobulin. |